NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, announced that its broad-spectrum antiviral candidate NV-387 warrants evaluation as a potential treatment option for the rapidly expanding Bundibugyo strain Ebola outbreak in Africa. The company noted the absence of approved vaccines or therapies specifically targeting this virus strain, highlighting the urgent need for effective countermeasures.
NV-387 employs a host-targeted antiviral mechanism, which may reduce the likelihood of viral resistance, and is formulated as an oral drug. These characteristics could offer significant advantages in outbreak settings where treatment delivery and healthcare worker safety are critical. The company is already preparing NV-387 for a Phase II clinical trial in the Democratic Republic of Congo for mpox, which could support near-term regional availability if the drug is found effective against Ebola.
"The Bundibugyo Ebola outbreak is a growing concern, and we believe NV-387's unique properties make it a strong candidate for evaluation," said a company spokesperson. The drug's oral formulation simplifies administration and reduces the need for injection equipment, potentially lowering the risk of needlestick injuries among healthcare workers.
NanoViricides' lead drug candidate NV-387 is being developed for multiple viral infections, including RSV, COVID-19, influenza, and mpox. The company's nanoviricide technology, based on intellectual property from TheraCour Pharma, Inc., involves creating specially designed nanomaterials that target viruses directly.
For more details on the announcement, visit the full press release at https://ibn.fm/aSF5Z.
The company's newsroom provides updates on NNVC at https://ibn.fm/NNVC.
The Bundibugyo strain of Ebola virus was first identified in Uganda in 2007 and has caused multiple outbreaks with varying mortality rates. The current outbreak in Africa has raised alarms due to its rapid expansion, and the lack of specific treatments underscores the importance of broad-spectrum antiviral candidates like NV-387.
NanoViricides continues to advance its pipeline, with NV-387 positioned as a versatile platform against emerging viral threats. The company's focus on host-targeted mechanisms and oral delivery could provide a critical tool in pandemic preparedness and response.
